MADRID, 21 Sep. (EUROPA PRESS) –
Roche has announced interim data from the randomized phase II coopERA trial in breast cancer, evaluating neoadjuvant treatment with giredestrant (formerly known as GDC-9545), a new generation oral selective estrogen receptor degrader (SERD) in phase research, in postmenopausal women with RE-positive and HER2-negative early breast cancer.
In the window of opportunity phase, after 14 days of treatment, giredestrant showed a greater reduction in Ki67, a prognostic marker that measures tumor proliferation, compared to anastrozole (80% vs 67% respectively). The safety profile of giredestrant was consistent with previous trials and fewer patients experienced side effects related to giredestrant versus anastrozole.
The results of the interim analysis of the coopERA study have been presented at the Congress of the European Society for Medical Oncology (ESMO) in 2021 and the data of the primary analysis will be released at an upcoming scientific meeting.
“We are excited to share the first data from the giredestrant randomized phase II trial showing promising activity and safety against RH-positive, HER2-negative early breast cancer,” said Dr. Levi Garraway, Chief Medical Officer. and Head of Global Product Development at Roche.
“Our ongoing comprehensive program for RH-positive breast cancer aims to address the significant unmet needs of people who continue to experience a major impact on their quality of life, including the risk of treatment resistance and recurrence of breast cancer. disease, “he added.
–
